The high cost of stroke to society, the family, and the patient

Pharmacotherapy

Volumn 18, Issue 3 II SUPPL., 1998, Pages

  Horner, Ronald D ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

CAREGIVER; CAROTID ENDARTERECTOMY; DISABILITY; FAMILY; HEALTH CARE COST; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; REVIEW; RISK FACTOR; SOCIETY; STROKE;

CEREBROVASCULAR DISORDERS; FAMILY; HEALTH EDUCATION; HUMANS; RISK FACTORS;

EID: 0031804581     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. American Heart Association. Heart and stroke facts: 1996 statistical supplement. Dallas: American Heart Association, 1996.
2. Modan B, Wagener DK. Some epidemiological aspects of stroke: mortality/morbidity trends, age, sex, race, socioeconomic status. Stroke 1992;23:1230-6.
3. Centers for Disease Control and Prevention. Cerebrovascular disease mortality and Medicare hospitalization - United States, 1980-1990. MMWR 1992;41:477-80.
4. Wolf PA, D'Agostino RB, O'Neal MA. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke 1992;23:1551-5.
5. Matchar DB, Duncan PT. Cost of stroke. Stroke Clinical Updates 1994;5:9-12.
6. Samsa GP, Matchar DB, Bonito A, et al. Utilities for major stroke: results from a nationally diverse survey of persons at increased risk for stroke. Am Heart J In press.
7. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke 1994;25: 1721-5.
8. Gresham GE, Fitzpatrick TE, Wolf PA, McNamara PM, Kannel WB, Dawber TR. Residual disability in survivors of stroke - the Framingham Study. N Engl J Med 1975; 293:954-6.
9. Gresham GE, Phillips TF, Wolf PA, McNamara PM, Kannel WB, Dawber TR. Epidemiologic profile of long-term stroke disability: the Framingham Study. Arch Phys Med Rehabil 1979;60:487-91.
10. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The stroke data bank: design, methods, and baseline characteristics. Stroke 1988;19:547-54.
11. Gresham GE, Duncan PW, Stason WB, et al. Post-stroke rehabilitation, clinical practice guideline no. 16. Rockville, MD: Public Health Service, Agency for Health Care Policy and Research; 1995. U.S. Department of Health and Human Services publication 95-0662.
12. Åström M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke 1993;24:976-82.
13. Glass TA, Matchar DB, Belyea M, Feussner JR. Impact of social support on outcome in first stroke. Stroke 1993;24:64-70.
14. Anderson CS, Linto J, Stewart-Wynne EG. A population-based assessment of the impact and burden of caregiving for long-term stroke survivors. Stroke 1995;26:843-9.
15. Elmståhl S, Malmberg B, Annerstedt L. Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale. Arch Phys Med Rehabil 1996;77:177-82.
16. Zweifler RM, Lyden PD, Taft B, Kelly N, Rothrock JF. Impact of race and ethnicity on ischemic stroke: the University of California at San Diego Stroke Data Bank. Stroke 1995;26:245-8.
17. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke: the Oxfordshire community stroke project. Stroke 1994;25: 333-7.
18. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham Study. Stroke 1982;13:290-5.
19. Gorelick PB. Stroke prevention: an opportunity for efficient utilization of health care resources during the coming decades. Stroke 1994;25:220-4.
20. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332: 238-48.
21. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-53.
22. Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim LL, Holme I. Benefit of a stroke unit: a randomized controlled trial. Stroke 1991;22:1026-31.
23. Jorgensen HS, Nakayama H, Raaschou HO, Larsen K, Hübbe P, Olsen TS. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study. Stroke 1995;26: 1178-82.
24. Langhorne P, Williams BO, Gilchrist W, Howie K. Do stroke units save lives? Lancet 1993;342:395-7.
25. Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993;56:17-25.
26. Dorman PH, Counsell CE, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs 1996;5:457-74.
27. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
28. ® Product Information. Physicians' Desk Reference, 51st ed. Montvale, NJ: Medical Economics Company, Inc, 1997:1045-9.
29. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA 1990;263:65-8.
30. Alberts MJ, Perry A, Dawson DV, Bertels C. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke 1992;23:352-6.